From The Cutting Room Floor

  1. Immuno-Oncology — The Year’s News In Science

    In 2014, many of the most encouraging studies of checkpoint blockade went public at the annual ASCO (American Society of Clinical Oncology) meeting. This year, even more positive studies of new checkpoint inhibitors were reported.

  2. Combo Immuno-Oncology R&D Programs — Recent & Ongoing

    By careful estimate, companies will have a large number of combination cancer immunotherapy trials in planning or execution as of Jan. 1, 2016.

  3. Been There, Done That — Sound Advice If Considering Clinical Trial Participation

    I interviewed three people who participated in medical research. The goal of the discussion was to learn about their personal experiences in order to pass on any useful information that could help biopharmaceutical executives better design and execute future clinical trials. 

  4. What Sanofi’s Pascale Witz Learned About Leadership From Her 18 Years At GE

    According to Pascale Witz, EVP and leader of Sanofi’s global divisions and strategic development organization, one of the most important things you do as a leader is build the right team. “If you don’t have the right team behind you, you can’t do anything.” 

  5. Celgene's M&A Dealer - “The Best Career Decision I Ever Made.”

    For George Golumbeski, the key to becoming good at BD is learning by doing. “I was once asked, ‘What books can one read to learn about negotiations?’” he says. “Forget it. You’ve got to get in there. Hopefully you have somebody who can show you the ropes. And, you are probably going to mess up a few times.” 

  6. How Does Being A Scientist Help With Biopharmaceutical Business Development?

    Celgene’s SVP of business development, George Golumbeski, completed his undergraduate degree in biology, a Ph.D. in genetics, and a post doc in molecular biology. So what makes him qualified to run the business development unit for one of the hottest biopharmaceutical companies?

  7. Want To Know What Deal Celgene’s George Golumbeski Is Most Proud Of?

    George Golumbeski, Celgene’s SVP of business development, has been listed as one of the most influential folks in all of biotech, the result of the company’s consistent deal-making success, which is his primary role. When I asked him if he had a deal he was most proud of, he replied...

  8. A Behind-The-Scenes Look Into My Interview With CEO Of Jazz Pharmaceuticals

    The unfortunate reality of conducting interviews with biopharmaceutical executives is that not all of the interesting insights gained make it into the final published article. This is certainly true of the in-person interview I conducted with the cofounder, chairman, and CEO of Jazz Pharmaceuticals, Bruce Cozadd. 

  9. Do You Think Your CEO Meets With Your Customers Enough?

    Though seniority has the advantage of creating access, if you want to get access to customer knowledge, Bayer board member Kemal Malik's advice is not to make your title a focal point of the discussion. “If you go there as a senior person from the home office asking questions like, ‘Are we doing a good job?’ all you are going to get is, ‘Yes, you guys are fantastic.’” 


  10. Are You Learning From Failure To Get Better At Innovation?

     “If someone comes to me and says, ‘I've never failed or made a mistake,’ I'd get very worried about them, because they are basically saying they've never tried anything,” states Kemal Malik,the Bayer board of management member of global innovation.